The board (the "Board") of directors (the "Directors") of Hansoh Pharmaceutical Group Company Limited (the "Company", together with its subsidiaries, the "Group") announced that, on December 26, 2025, the Company entered into a license agreement (the "License Agreement") with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (the "Licensor"). Pursuant to the License Agreement, the Company obtained an exclusive license from the Licensor to develop, manufacture and commercialize SHR6508 (the "Product") in China (excludes Hong Kong, Macau and Taiwan), with the right of sublicense in accordance with the terms of the License Agreement.
The Company shall pay the Licensor an upfront payment of RMB30 million, potential regulatory and commercialization milestone payments of up to RMB190 million and tiered single- digit royalties on potential future product net sales. The Product is an allosteric modulator of the calcium-sensing receptor (CaSR) that increases the receptor's sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. The Product is currently in Phase III clinical trial and being developed for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease who require hemodialysis.
The Licensor is a leading innovative global pharmaceutical company rooted in China, the A shares of which have been listed on the Shanghai Stock Exchange (stock code: 600276) and the H shares of which are listed on Main Board of The Stock Exchange of Hong Kong Limited (stock code: 1276). The Licensor is principally engaged in the R&D, manufacture and sale of pharmaceutical products.
